Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0013362 (
dysarthria
)
3,768
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A 55-year-old man came to us with
dysarthria
and right hemiparesis. The cerebral angiography showed segmental narrowing and irregularity of the left anterior cerebral artery. The patient responded well to corticosteroid therapy and there was later angiographic evidence of healing. After systemic angiitis and central
nervous system infection
were excluded, the diagnosis of isolated benign cerebral vasculitis was made. According to past reports, at least 13 patients have been described as having isolated benign cerebral vasculitis. The common features of isolated benign cerebral vasculitis are as follows: 1) benign evolution, 2) sensitiveness to corticosteroids, 3) absence or minimal change of CSF findings, 4) angiographic pattern of arteritis, 5) the most common symptom is headache. We suggest that early corticosteroid therapy is necessary in any case of cerebral vasculitis.
...
PMID:[A case of what was regarded as isolated benign cerebral vasculitis]. 176 43
Two cases of cerebral vasculitis of the central nervous system are reported. In our cases, systemic investigation found no underlying cause for vasculitis. Case 1: A 59-year-old female presented severe headache due to subarachnoid hemorrhage. CT scan obtained one month later demonstrated a low density area with ring-like enhancement in the right frontal lobe. A surgical specimen revealed inflammation of the leptomenigeal vessels with many lymphocytes. Case 2: A 64-year-old female came to us with
dysarthria
and slight left hemiparesis. CT scan and MRI obtained after admission demonstrated an abnormal mass lesion with enhancement in the right frontal lobe. The histological examination revealed vasculitis. After systemic disease and central
nervous system infection
were excluded, we diagnosed this case as cerebral vasculitis of unknown origin. In this paper, the clinical and pathological features of cerebral vasculitis and differential diagnosis were discussed.
...
PMID:[Two cases of what was regarded as cerebral vasculitis]. 809 Feb 70
Progressive multifocal leukoencephalopathy (PML) is a central
nervous system infection
caused by John Cunningham (JC) virus reactivation in an immunocompromised patient. PML has various neurologic symptoms and has very poor prognosis. A 36-year-old man developed transverse myelitis and had a psychiatric disorder at the age of 26. He was diagnosed with systemic lupus erythematosus (SLE) and neuropsychiatric SLE (NPSLE), on the basis of leukopenia and presence of anti-DNA and anti-nuclear antibodies. Treatment with glucocorticoid (GC) was started, and remission was introduced. Six months before PML onset, his condition was complicated with hemophagocytic lymphohistiocytosis (HLH) due to exacerbation of SLE. Remission re-induction therapy by GC, cyclosporine-A, intravenous cyclophosphamide, and rituximab (RTX) was initiated and HLH improved. However, interleukin-6 levels of the cerebrospinal fluid (CSF) continued to rise. We thought that the disease activity of NPSLE worsened; thus, we introduced mycophenolate mofetil (MMF) 4 months before the PML onset. He developed progressive
dysarthria
and right hemiplegia. He was diagnosed with PML via magnetic resonance imaging and JC virus polymerase chain reaction in CSF. Considering that immunosuppressants, including RTX and MMF, are precipitating factors of PML, we discussed the RTX removal using plasma exchange (PEx), but we did not introduce PEx, because it was expected that the concentration of RTX was already lowered when he was diagnosed with PML. Treatment for PML with mefloquine and mirtazapine saved his life, but severe residual disabilities remained. This is the first report of a patient who developed PML during combination therapy with RTX and MMF.
...
PMID:A case of developing progressive multifocal leukoencephalopathy while using rituximab and mycophenolate mofetil in refractory systemic lupus erythematosus. 2998 69